Sera Prognostics, Inc., (SERA): Price and Financial Metrics


Sera Prognostics, Inc., (SERA): $1.53

0.01 (+0.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SERA Stock Price Chart Interactive Chart >

Price chart for SERA

SERA Price/Volume Stats

Current price $1.53 52-week high $15.50
Prev. close $1.52 52-week low $1.43
Day low $1.53 Volume 184
Day high $1.53 Avg. volume 73,418
50-day MA $2.48 Dividend yield N/A
200-day MA $7.13 Market Cap 47.27M

Sera Prognostics, Inc., (SERA) Company Bio


Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.


SERA Latest News Stream


Event/Time News Detail
Loading, please wait...

SERA Latest Social Stream


Loading social stream, please wait...

View Full SERA Social Stream

Latest SERA News From Around the Web

Below are the latest news stories about Sera Prognostics Inc that investors may wish to consider to help them evaluate SERA as an investment opportunity.

SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its presentation at the virtual Citi 2022 Healthcare Conference: Services, MedTech, Life Science Tools & HCIT, to be held February 23-24, 2022, has been rescheduled. Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will provide a company update and discuss Sera's latest achievemen

Yahoo | February 17, 2022

SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the virtual Citi 2022 Healthcare Conference: Services, MedTech, Life Science Tools & HCIT. Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will provide a

Yahoo | February 7, 2022

Sera Prognostics in pact with MultiPlan to expand market for PreTRM Test

Sera Prognostics <> has signed an agreement with MultiPlan to join its PHCS and MultiPlan Networks to widen the patient access to the company’s PreTRM Test, a blood-based…

Seeking Alpha | February 1, 2022

SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TEST

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks. The agreement will help expand access to the PreTRM® Test, the company's proprietary proteomic blood test for measuring a woman's risk of spontaneous preterm birth, to allow more timely inter

Yahoo | February 1, 2022

SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The addition is based on the annual reconstitution of the index announced by Nasdaq and will become effective prior to the U.S. stock market open on Monday, December 20, 2021.

Yahoo | December 15, 2021

Read More 'SERA' Stories Here

SERA Price Returns

1-mo -32.00%
3-mo -73.02%
6-mo -86.09%
1-year N/A
3-year N/A
5-year N/A
YTD -77.73%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.648 seconds.